How Peptides Are Studied

Peptide research typically progresses through in vitro cell work, animal models, early-phase human safety studies, and then larger controlled trials. Each rung answers a different question, and results rarely transfer cleanly upward.

A compound with dozens of impressive rodent studies and no human trials is not a well-evidenced compound in humans. This is the single most common misreading of the peptide literature.

Animal models allow controlled injury, controlled dosing and tissue-level measurement that would be impossible in humans. They are indispensable for establishing a mechanism.

They also differ from humans in metabolism, dose scaling and disease biology. Allometric scaling between species is an approximation, and many compounds that perform well in rodents fail in human trials.

Phase 1 studies test safety and pharmacokinetics in a small group. Phase 2 tests whether the compound does anything measurable and explores dose. Phase 3 tests it against a comparator or placebo in a large population.

Registration on a public trials registry, peer-reviewed publication of results, and independent replication are the three signals that most strengthen a finding.

How many subjects were included? Was there a control group? Was the study blinded? Was the primary endpoint pre-specified, or chosen after the data came in?

Small, unblinded, uncontrolled studies with post-hoc endpoints are common in the peptide literature. They are useful for generating hypotheses and poor for drawing conclusions.